Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 55 clinical trials
Featured trial
A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study Comparing the Efficacy, Safety and Tolerability of ABBV-951 to Oral Carbidopa/Levodopa in Advanced Parkinson's Disease Patients

The purpose of this study is to find out how well ABBV-951 works to control Parkinson's disease symptoms compared to oral Carbidopa (CD)/Levodopa (LD). The study is also

carbidopa
levodopa
  • 131 views
  • 23 Nov, 2020
  • 1 location
Featured trial
A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Patients With Motor Fluctuations

To evaluate the safety and efficacy of IPX203 (carbidopa and levodopa) extended-release capsules (IPX203 ER CD-LD) in comparison to immediate release (IR) CD-LD in the

illicit drug
  • 139 views
  • 23 Nov, 2020
  • 1 location
Featured trial
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Phase to Determine the Efficacy and Safety of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease Experiencing End of Dose "Wearing-Off" (TOZ-PD)

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Phase to Determine the Efficacy and Safety of Tozadenant as Adjunctive Therapy in Levodopa-Treated

  • 222 views
  • 23 Nov, 2020
  • 1 location
Featured trial
Open Label Parkinson's clinical research study

Open Label Parkinson's clinical research study

  • 716 views
  • 25 Mar, 2021
  • 1 location
Combination Therapy With Fecal Microbiota Transplantation and Vedolizumab for Induction of Ulcerative Colitis

The project intends to assess the polygenic burden of rare disruptive mutations in Parkinson's disease (PD) and how they influence the phenotype/pathological heterogeneity of disease.

fecal microbiota transplantation
vedolizumab
microbiota
enemas
tumor necrosis factor
  • 0 views
  • 16 Sep, 2021
  • 1 location
TAME-PD - Physical Therapy, Atomoxetine and, Methylphenidate, to Enhance Gait and Balance in Parkinson's Disease (TAME-PD)

Gait and balance problems are a significant source of disability in patients with Parkinson disease. Physical therapy remains one of the main treatments. On the other hand some medications, such as methyphenidate and atomoxetine, have been tried with promising results. The outcomes in gait and balance in Parkinson disease after …

medication regimen
  • 18 views
  • 23 Mar, 2022
  • 1 location
Enhancement of Stroke Rehabilitation With Levodopa (ESTREL)

Trial investigates the benefits and harms of Levodopa /Carbidopa 100/25mg compared to placebo (given in addition to standardized rehabilitation based on the principles of motor learning) and

  • 2 views
  • 27 Apr, 2022
  • 9 locations
A Clinical Study of Mesdopetam in Patients With Parkinson's Disease Experiencing Levodopa Induced Dyskinesia

This is a Phase 2b study investigating the efficacy and safety of mesdopetam as adjunct therapy on daily ON-time without troublesome dyskinesia in patients with Parkinson disease. Mesdopetam is taken for 84 days.

apomorphine
levodopa
dyskinesia
  • 0 views
  • 24 Mar, 2022
  • 28 locations
A Study in Parkinson's Disease in Patients With Moderate to Severe Dyskinesia (ASTORIA)

The current study will explore the efficacy, safety and tolerability of 2 dose combinations of JM-010 to determine the optimal doses of each component to be studied in confirmatory clinical trials.

parkinson's disease
levodopa
dyskinesia
combinations
  • 10 views
  • 02 May, 2022
  • 4 locations
Psychological Effects of Levodopa in Parkinson's Disease

The investigators aim is to study neuropsychiatric symptoms and underlying abnormalities in resting-state fMRI in patients with Parkinson's disease (PD) suffering from neuropsychiatric fluctuations, to enhance the understanding of the pathophysiological mechanisms underlying neuropsychiatric symptoms.

levodopa
antiparkinsonian agents
  • 0 views
  • 26 Mar, 2022